Patent Trouble

Genentech has accused the University of Pennsylvania of committing "patent fraud," reports The Daily Pennsylvanian's Laura Cofsky. The company is suing the school over a cancer treatment they both say is theirs, Cofsky says. Penn tested the treatment on transgenic mice engineered to develop cancer, and accused Genentech of patent infringement when the school noticed a patent from the company for the same treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.